Lucidigm Therapeutics

Lucidigm Therapeutics is developing innovative immunomodulatory biologics for organ transplantation, gene therapy and autoimmune disease.
Co-Founder Zac Elmore, Ph.D. presented Lucidigm Therapeutics, a seven-month-old company spun out of Duke that is using engineered enzymes to modulate immune responses. They are seeking seed funding to develop highly specific enzymes that could be helpful in preventing transplanted organ rejection, improving gene therapy and treating autoimmune diseases. Lucidigm has used data-mining and training algorithms to discover new enzymes that precisely target immunoglobulins IgM and IgG, which are types of antibodies that orchestrate immune responses. In the discussion of first in class versus best in class, "we are both,” Elmore said.
https://today.duke.edu/2023/09/duke-companies-and-faculty-share-ideas-investors-triangle-venture-day